Astria Therapeutics to Showcase Innovations at 2025 HAEi Regional Conference EMEA
Astria Therapeutics is set to make a significant impact at the 2025 HAEi Regional Conference EMEA in Rome, Italy. The biopharmaceutical company will present two key posters and an oral presentation, highlighting its innovative work in treating hereditary angioedema and atopic dermatitis.
Dr. William Lumry, a distinguished medical professional, will be leading these presentations. On October 11, he will deliver an oral presentation titled 'Results From The ALPHA-STAR Trial' at 9:45am CEST. This presentation will focus on the safety and efficacy of navenibart, Astria's lead program. Navenibart is a monoclonal antibody inhibitor of plasma kallikrein, designed specifically for treating hereditary angioedema.
Later that day, Dr. Lumry will also present a poster titled 'ALPHA-ORBIT' at 6:30pm CEST. This poster will provide insights into another aspect of Astria's work in hereditary angioedema treatment.
In addition to these presentations, Astria will also showcase its second program, STAR-0310. This is an investigational monoclonal antibody OX40 antagonist, currently under investigation for treating atopic dermatitis.
Astria Therapeutics' participation in the 2025 HAEi Regional Conference EMEA is a testament to its commitment to advancing treatments for hereditary angioedema and atopic dermatitis. The company's presentations, led by Dr. William Lumry, are expected to provide valuable insights into its innovative pipeline and potential future therapies.
